Abstract Body

Background

Following HIV infection, autologous antibodies (aAbs) develop against the viral envelope protein (Env). aAbs cannot clear HIV because of Env’s glycosylation patterns and escape mutation toleration. Antiretroviral treatment (ART) suppresses viral replication, but does not eliminate latent reservoirs, underscoring the need for HIV cure. Broadly neutralizing antibodies (bNAbs), which target conserved regions including the CD4 binding site (CD4bs) are being tested clinically (e.g. VRC01, VRC07 and 3BNC117). However, virus escape still occurs, and there is a need to know how aAbs affect bNAb therapy escape.

Methods

Using a Meso Scale Discovery binding assay, 4 biotinylated HIV Env proteins (gp120, gp41, RSC3, RSC3 ∆371I) were linked to spots on a multiplexed plate. RSC3 is a CD4bs resurfaced stabilized core and RSC3 ∆371I is a matched knockout variant. aAbs targeting the CD4bs should bind the former but not the latter. IgG was purified from the A5340 (13 participants receiving VRC01 during ART interruption) and the VRC607 and 601 (22 participants receiving VRC07-523 or VRC01 while viremic) clinical trials. IgG was serially diluted 5-fold for a 7-point series. Total and IgG subclass 1-4 specific responses were detected. Positivity for gp120 or gp41 autologous responses were RLU values >450 at the highest Ig concentration. CD4bs responses were defined as a >4-fold difference between RSC3 and RSC3 ∆371I at the highest Ig concentration.

Results

All participants had detectable gp120 and gp41 responses, mainly IgG1 and IgG2, while IgG4 responses were infrequent. IgG3 responses differed by ART status: of participants on ART 46% had gp120 and 23% had gp41 responses, but in viremic participants these responses were 95% and 100% respectively. CD4bs-directed aAbs were detected in 71% of participants and were IgG1. Using our positivity threshold (>4-fold difference between RSC3 and RSC3 ∆371I), no association was observed between autologous CD4bs antibodies and pre-infusion VRC01 susceptibility when the 3 cohorts were combined. Trends suggest this relationship varies by ART status. Participants on ART tended to have decreased VRC01 sensitivity in the presence of CD4bs responses but the opposite was observed in viremic participants.

Conclusions

Autologous CD4bs-specific aAbs are common in people living with HIV but do not correlate with VRC01 sensitivity using our threshold. These findings suggest that while aAbs target the same epitopes as bNAbs, they may not influence clinical outcome.

Table or Figure